Skip to main content
NeuroRx logoLink to NeuroRx
. 2012 Sep 5;3(2):276–291. doi: 10.1016/j.nurx.2006.01.001

Advances in treatment of pediatric brain tumors

Patricia L Robertson 1,
PMCID: PMC3593436  PMID: 16554265

Summary

The long-term survival of children with brain tumor has improved considerably in the last three decades, owing to advances in neuroimaging, neurosurgical, and radiation therapy modalities, coupled with the application of conventional chemotherapy. MRI, MR spectroscopy and diffusion-weighted MRI have contributed to more accurate diagnosis, prognostication and better treatment planning. Neurosurgical treatment has been advanced by the use of functional MRI, and intraoperative image-guided stereotactic techniques and electrophysiologic monitoring. The use of 3-D conformai and intensity-modulated radiation therapy, stereotactic radiosurgery, and radiosensitizing agents has made radiation therapy safer and more effective. Conventional chemotherapy, administered either alone or combined with radiation therapy has improved survival and quality of life of children with brain tumors. These improved outcomes have also occurred, due, in part, to their treatment on collaborative national and international studies. Recent promising diagnostic and therapeutic strategies have resulted from advances in understanding molecular brain tumor biology. Important new approaches include the refinement of drug-delivery strategies, the evaluation of biologic markers to stratify patients for optimal treatment and to exploit these molecular differences using “targeted” therapeutic strategies. These approaches include blocking tumor cell drug resistance mechanisms, immunotherapy, inhibition of molecular signal transduction pathways important in tumorigenesis, anti-angiogenic therapy, and gene therapy. The thrust of such approaches for children with brain tumors is especially directed at reducing the toxicity of therapy and improving quality-of-life, as well as increasing disease-free survival.

Key Words: Pediatric brain tumor, neurosurgery, radiation therapy, chemotherapy, immunotherapy, small molecule

References

  • 1.Rosser T, Packer RJ. Intracranial neoplasms in children with neurofibromatosis 1. J Child Neurol. 2002;17(8):630–637. doi: 10.1177/088307380201700815. [DOI] [PubMed] [Google Scholar]
  • 2.Robertson PL, Allen JC, Abbott IR, Miller DC, Fidel J, Epstein FJ. Cervicomedullary tumors in children: a distinct subset of brainstem gliomas. Neurology. 1994;44(10):1798–1803. doi: 10.1212/WNL.44.10.1798. [DOI] [PubMed] [Google Scholar]
  • 3.Albright AL, Packer RJ, Zimmerman R, Rorke LB, Boyett J, Hammond GD. Magnetic resonance scans should replace biopsies for the diagnosis of diffuse brain stem gliomas: a report from the Children’s Cancer Group. Neurosurgery. 1993;33(6):1026–1029. doi: 10.1227/00006123-199312000-00010. [DOI] [PubMed] [Google Scholar]
  • 4.Law M. MR spectroscopy of brain tumors. Top Magn Reson Imaging. 2004;15(5):291–313. doi: 10.1097/00002142-200410000-00003. [DOI] [PubMed] [Google Scholar]
  • 5.Warren KE, Frank JA, Black JL, Hill RS, Duyn JH, Aikin AA, Lewis BK, Adamson PC, Balis FM. Proton magnetic resonance spectroscopic imaging in children with recurrent primary brain tumors. J Clin Oncol. 2000;18(5):1020–1026. doi: 10.1200/JCO.2000.18.5.1020. [DOI] [PubMed] [Google Scholar]
  • 6.Chenevert TL, Meyer CR, Moffat BA, Rehemtulla A, Mukherji SK, Gebarski SS, Quint DJ, Robertson PL, Lawrence TS, Junck L, Taylor JM, Johnson TD, Dong Q, Muraszko KM, Brunberg JA, Ross BD. Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy. Mol Imaging. 2002;1(4):336–343. doi: 10.1162/153535002321093945. [DOI] [PubMed] [Google Scholar]
  • 7.Moffat BA, Chenevert TL, Lawrence TS, Meyer CR, Johnson TD, Dong Q, Tsien C, Mukherji S, Quint DJ, Gebarski SS, Robertson PL, Junck LR, Rehemtulla A, Ross BD. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci USA. 2005;102(15):5524–5529. doi: 10.1073/pnas.0501532102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133(4):1710–1715. [PubMed] [Google Scholar]
  • 9.Pollack IF, Hamilton RL, Burnham J, Holmes EJ, Finkelstein SD, Sposto R, Yates AJ, Boyett JM, Finlay JL. Impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort. Neurosurgery. 2002;50(6):1238–1244. doi: 10.1097/00006123-200206000-00011. [DOI] [PubMed] [Google Scholar]
  • 10.Fisher BJ, Naumova E, Leighton CC, Naumov GN, Kerklviet N, Fortin D, Macdonald DR, Caimcross JG, Bauman GS, Stitt L. Ki-67: a prognostic factor for low-grade glioma? Int J Radiat Oncol Biol Phys. 2002;52(4):996–1001. doi: 10.1016/S0360-3016(01)02720-1. [DOI] [PubMed] [Google Scholar]
  • 11.Grotzer MA, Geoerger B, Janss AJ, Zhao H, Rorke LB, Phillips PC. Prognostic significance of Ki-67 (MIB-1) proliferation index in childhood primitive neuroectodermal tumors of the central nervous system. Med Pediatr Oncol. 2001;36(2):268–273. doi: 10.1002/1096-911X(20010201)36:2<268::AID-MPO1064>3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
  • 12.Pollack IF, Finkelstein SD, Burnham J, Holmes EJ, Hamilton RL, Yates AJ, Finlay JL, Sposto R. Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort. Cancer Res. 2001;61(20):7404–7407. [PubMed] [Google Scholar]
  • 13.Tremont-Lukats IW, Gilbert MR. Advances in molecular therapies in patients with brain tumors. Cancer Control. 2003;10(2):125–137. doi: 10.1177/107327480301000204. [DOI] [PubMed] [Google Scholar]
  • 14.Pollack IF, Finkelstein SD, Woods J, Burnham J, Holmes EJ, Hamilton RL, Yates AJ, Boyett JM, Finlay JL, Sposto R. Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med. 2002;346(6):420–427. doi: 10.1056/NEJMoa012224. [DOI] [PubMed] [Google Scholar]
  • 15.Sung T, Miller DC, Hayes RL, Alonso M, Yee H, Newcomb EW. Referential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas. Brain Pathol. 2000;10(2):249–259. doi: 10.1111/j.1750-3639.2000.tb00258.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Segal RA, Goumnerova LC, Kwon YK, Stiles CD, Pomeroy SL. Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci U S A. 1994;91(26):12867–12871. doi: 10.1073/pnas.91.26.12867. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Scheurlen WG, Schwabe GC, Joos S, Mollenhauer J, Sorensen N, Kuhl J. Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. J Clin Oncol. 1998;16(7):2478–2485. doi: 10.1200/JCO.1998.16.7.2478. [DOI] [PubMed] [Google Scholar]
  • 18.Packer RJ, Cogen P, Vezina G, Rorke LB. Medulloblastoma: clinical and biologic aspects. Neuro-oncol. 1999;1(3):232–250. doi: 10.1215/15228517-1-3-232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Pingoud-Meier C, Lang D, Janss AJ, Rorke LB, Phillips PC, Shalaby T, Grotzer MA. Loss of caspase-8 protein expression correlates with unfavorable survival outcome in childhood medulloblastoma. Clin Cancer Res. 2003;9(17):6401–6409. [PubMed] [Google Scholar]
  • 20.Taipale J, Chen JK, Cooper MK, Wang B, Mann RK, Milenkovic L, Scott MP, Beachy PA. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature. 2000;406(6799):1005–1009. doi: 10.1038/35023008. [DOI] [PubMed] [Google Scholar]
  • 21.MacDonald TJ, Brown KM, LaFleur B, Peterson K, Lawlor C, Chen Y, Packer RJ, Cogen P, Stephan DA. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet. 2001;29(2):143–152. doi: 10.1038/ng731. [DOI] [PubMed] [Google Scholar]
  • 22.Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau C, Allen JC, Zagzag D, Olson JM, Curran T, Wetmore C, Biegel JA, Poggio T, Mukherjee S, Rifkin R, Califano A, Stolovitzky G, Louis DN, Mesirov JP, Lander ES, Golub TR. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002;415(6870):436–442. doi: 10.1038/415436a. [DOI] [PubMed] [Google Scholar]
  • 23.Biegel JA, Zhou JY, Rorke LB, Stenstrom C, Wainwright LM, Fogelgren B. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res. 1999;59(1):74–79. [PubMed] [Google Scholar]
  • 24.Rezai AR, Mogilner AY, Cappell J, Hund M, Llinas RR, Kelly PJ. Integration of functional brain mapping in image-guided neurosurgery. Acta Neurochir Suppl. 1997;68:85–89. doi: 10.1007/978-3-7091-6513-3_16. [DOI] [PubMed] [Google Scholar]
  • 25.Duffner PK, Horowitz ME, Krischer JP, Burger PC, Cohen ME, Sanford RA, Friedman HS, Kun LE. The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. Neuro-oncol. 1999;1(2):152–161. doi: 10.1093/neuonc/1.2.152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Kun L. Principles of Radiation Therapy. 2 ed. New York: Raven Press; 1994. pp. 95–115. [Google Scholar]
  • 27.Swift P. Novel techniques in the delivery of radiation in pediatric oncology. Pediatr Clin North Am. 2002;49(5):1107–1129. doi: 10.1016/S0031-3955(02)00037-8. [DOI] [PubMed] [Google Scholar]
  • 28.Hodgson DC, Goumnerova LC, Loeffler JS, Dutton S, Black PM, Alexander E, Xu R, Kooy H, Silver B, Tarbell NJ. Radiosurgery in the management of pediatric brain tumors. Int J Radiat Oncol Biol Phys. 2001;50(4):929–935. doi: 10.1016/S0360-3016(01)01518-8. [DOI] [PubMed] [Google Scholar]
  • 29.Allen J, Siffert J, Donahue B, Nirenberg A, Jakacki R, Robertson P, DaRosso R, Thoron L, Rosovsky M, Pinto R. A phase I/II study of carboplatin combined with hyperfractionated radiotherapy for brainstem gliomas. Cancer. 1999;86(6):1064–1069. doi: 10.1002/(SICI)1097-0142(19990915)86:6<1064::AID-CNCR24>3.0.CO;2-1. [DOI] [PubMed] [Google Scholar]
  • 30.Ostryszja L: Gemcitabine and radiosensitization in two glioblasoma cell lines.Prec Amer Assoc Cancer Res (30): 382, 1998.
  • 31.Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M, Kobayashi T, Yoshida S, Abe T, Narita M, Takahashi M, Tanaka R. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res. 2005;11(11):4160–4167. doi: 10.1158/1078-0432.CCR-05-0120. [DOI] [PubMed] [Google Scholar]
  • 32.De Vleeschouwer S, Van Calenbergh F, Demaerel P, Flamen P, Rutkowski S, Kaempgen E, Wolff JE, Plets C, Sciot R, Van Gool SW. Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report. J Neurosurg. 2004;100:492–497. doi: 10.3171/ped.2004.100.5.0492. [DOI] [PubMed] [Google Scholar]
  • 33.Lumniczky K, Desaknai S, Mangel L, Szende B, Hamada H, Hidvegi EJ, Safrany G. Local tumor irradiation augments the antitumor effect of cytokine-producing autologous cancer cell vaccines in a murine glioma model. Cancer Gene Ther. 2002;9(1):44–52. doi: 10.1038/sj.cgt.7700398. [DOI] [PubMed] [Google Scholar]
  • 34.Boskovitz A, Wikstrand CJ, Kuan CT, Zalutsky MR, Reardon DA, Bigner DD. Monoclonal antibodies for brain tumour treatment. Expert Opin Biol Ther. 2004;4(9):1453–1471. doi: 10.1517/14712598.4.9.1453. [DOI] [PubMed] [Google Scholar]
  • 35.Martell LA, Agrawal A, Ross DA, Muraszko KM. Efficacy of transferrin receptor-targeted immunotoxins in brain tumor cell lines and pediatric brain tumors. Cancer Res. 1993;53(6):1348–1353. [PubMed] [Google Scholar]
  • 36.Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol. 2003;65(1):3–13. doi: 10.1023/A:1026246500788. [DOI] [PubMed] [Google Scholar]
  • 37.Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature. 2001;411(6835):349–354. doi: 10.1038/35077219. [DOI] [PubMed] [Google Scholar]
  • 38.Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002;2(10):727–739. doi: 10.1038/nrc905. [DOI] [PubMed] [Google Scholar]
  • 39.Puduvalli VK, Sawaya R. Antiangiogenesis — therapeutic strategies and clinical implications for brain tumors. J Neurooncol. 2000;50(1-2):189–200. doi: 10.1023/A:1006469830739. [DOI] [PubMed] [Google Scholar]
  • 40.MacDonald TJ, Taga T, Shimada H, Tabrizi P, Zlokovic BV, Cheresh DA, Laug WE. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery. 2001;48(1):151–157. doi: 10.1097/00006123-200101000-00026. [DOI] [PubMed] [Google Scholar]
  • 41.Parsa A. Gene Therapy in Tumor of the Pediatric Central nervous System. In: Keating R, editor. Tumor of the Pediatric Netral Nervous System. New York: Thieme; 2001. pp. 184–195. [Google Scholar]
  • 42.Izquierdo M, Martin V, de Felipe P, Izquierdo JM, Perez-Higueras A, Cortes ML, Paz JF, Isla A, Blazquez MG. Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy. Gene Ther. 1996;3(6):491–495. [PubMed] [Google Scholar]
  • 43.Packer RJ, Raffel C, Villablanca JG, Tonn JC, Burdach SE, Burger K, LaFond D, McComb JG, Cogen PH, Vezina G, Kapcala LP. Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. J Neurosurg. 2000;92(2):249–254. doi: 10.3171/jns.2000.92.2.0249. [DOI] [PubMed] [Google Scholar]
  • 44.Manome Y, Wen PY, Dong Y, Tanaka T, Mitchell BS, Kufe DW, Fine HA. Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nat Med. 1996;2(5):567–573. doi: 10.1038/nm0596-567. [DOI] [PubMed] [Google Scholar]
  • 45.Cogen PH, McDonald JD. Tumor suppressor genes and medulloblastoma. J Neurooncol. 1996;29(1):103–112. doi: 10.1007/BF00165523. [DOI] [PubMed] [Google Scholar]
  • 46.Cheney IW, Johnson DE, Vaillancourt MT, Avanzini J, Morimoto A, Demers GW, Wills KN, Shabram PW, Bolen JB, Tavtigian SV, Bookstein R. Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer. Cancer Res. 1998;58(11):2331–2334. [PubMed] [Google Scholar]
  • 47.Gondi CS, Lakka SS, Yanamandra N, Olivero WC, Dinh DH, Gujrati M, Tung CH, Weissleder R, Rao JS. Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas. Cancer Res. 2004;64(12):4069–4077. doi: 10.1158/0008-5472.CAN-04-1243. [DOI] [PubMed] [Google Scholar]
  • 48.Rorke LB. The cerebellar medulloblastoma and its relationship to primitive neuroectodermal tumors. J Neuropathol Exp Neurol. 1983;42(1):1–15. doi: 10.1097/00005072-198301000-00001. [DOI] [PubMed] [Google Scholar]
  • 49.Duffner PK, Cohen ME, Myers MH, Heise HW. Survival of children with brain tumors: SEER Program, 1973–1980. Neurology. 1986;36(5):597–601. doi: 10.1212/WNL.36.5.597. [DOI] [PubMed] [Google Scholar]
  • 50.Dirks PB, Harris L, Hoffman HJ, Humphreys RP, Drake JM, Rutka JT. Supratentorial primitive neuroectodermal tumors in children. J Neurooncol. 1996;29(1):75–84. doi: 10.1007/BF00165520. [DOI] [PubMed] [Google Scholar]
  • 51.Albright AL, Wisoff JH, Zeltzer PM, Boyett JM, Rorke LB, Stanley P. Effects of medulloblastoma resections on outcome in children: a report from the Children’s Cancer Group. Neurosurgery. 1996;38(2):265–271. doi: 10.1097/00006123-199602000-00007. [DOI] [PubMed] [Google Scholar]
  • 52.Albright AL, Wisoff JH, Zeltzer P, Boyett J, Rorke LB, Stanley P, Geyer JR, Milstein JM. Prognostic factors in children with supratentorial (nonpineal) primitive neuroectodermal tumors. A neurosurgical perspective from the Children’s Cancer Group. Pediatr Neurosurg. 1995;22(1):1–7. doi: 10.1159/000121292. [DOI] [PubMed] [Google Scholar]
  • 53.Evans AE, Jenkin RD, Sposto R, Ortega JA, Wilson CB, Wara W, Ertel IJ, Kramer S, Chang CH, Leikin SL, et al. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg. 1990;72(4):572–582. doi: 10.3171/jns.1990.72.4.0572. [DOI] [PubMed] [Google Scholar]
  • 54.Krischer JP, Ragab AH, Kun L, Kim TH, Laurent JP, Boyett JM, Cornell CJ, Link M, Luthy AR, Camitta B. Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Group study. J Neurosurg. 1991;74(6):905–909. doi: 10.3171/jns.1991.74.6.0905. [DOI] [PubMed] [Google Scholar]
  • 55.Tait DM, Thomton-Jones H, Bloom HJ, Lemerle J, Morris-Jones P. Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I) Eur J Cancer. 1990;26(4):464–469. [PubMed] [Google Scholar]
  • 56.Packer RJ, Sutton LN, Elterman R, Lange B, Goldwein J, Nicholson HS, Mulne L, Boyett J, D’Angio G, Wechsler-Jentzsch K, et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg. 1994;81(5):690–698. doi: 10.3171/jns.1994.81.5.0690. [DOI] [PubMed] [Google Scholar]
  • 57.Strother D, Ashley D, Kellie SJ, Patel A, Jones-Wallace D, Thompson S, Heideman R, Benaim E, Krance R, Bowman L, Gajjar A. Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study. J Clin Oncol. 2001;19(10):2696–2704. doi: 10.1200/JCO.2001.19.10.2696. [DOI] [PubMed] [Google Scholar]
  • 58.Reddy AT, Janss AJ, Phillips PC, Weiss HL, Packer RJ. Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy. Cancer. 2000;88(9):2189–2193. doi: 10.1002/(SICI)1097-0142(20000501)88:9<2189::AID-CNCR27>3.0.CO;2-G. [DOI] [PubMed] [Google Scholar]
  • 59.Thomas PR, Deutsch M, Kepner JL, Boyett JM, Krischer J, Aronin P, Albright L, Allen JC, Packer RJ, Linggood R, Mulhern R, Stehbens JA, Langsten J, Stanley P, Duffner P, Rorke L, Cherlow J, Friedman HS, Finlay JL, Vietti TJ, Kun LE. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol. 2000;18(16):3004–3011. doi: 10.1200/JCO.2000.18.16.3004. [DOI] [PubMed] [Google Scholar]
  • 60.Jakacki RI, Feldman H, Jamison C, Boaz JC, Luerssen TG, Timmerman R. A pilot study of preirradiation chemotherapy and 1800 cGy craniospinal irradiation in young children with medulloblastoma. Int J Radiat Oncol Biol Phys. 2004;60(2):531–536. doi: 10.1016/j.ijrobp.2004.03.027. [DOI] [PubMed] [Google Scholar]
  • 61.Bailey CC, Gnekow A, Wellek S, Jones M, Round C, Brown J, Phillips A, Neidhardt MK. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Med Pediatr Oncol. 1995;25(3):166–178. doi: 10.1002/mpo.2950250303. [DOI] [PubMed] [Google Scholar]
  • 62.Wara WM, Le QT, Sneed PK, Larson DA, Prados MD, Levin VA, Edwards MS, Weil MD. Pattern of recurrence of medulloblastoma after low-dose craniospinal radiotherapy. Int J Radiat Oncol Biol Phys. 1994;30(3):551–556. doi: 10.1016/0360-3016(92)90940-J. [DOI] [PubMed] [Google Scholar]
  • 63.Packer RJ: 2340cGy of Craniospinal Radiotherapy (CSRT) plus Chemotherapy for Children with “Average-Risk” Medulloblastoma (MB): A Prospective Randomized Children’s Oncology Group Study (A9961).Society for Neuroncology Meeting, 2004.
  • 64.Geyer JR, Zeltzer PM, Boyett JM, Rorke LB, Stanley P, Albright AL, Wisoff JH, Milstein JM, Allen JC, Finlay JL, et al. Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: a report from the Childrens Cancer Group. J Clin Oncol. 1994;12(8):1607–1615. doi: 10.1200/JCO.1994.12.8.1607. [DOI] [PubMed] [Google Scholar]
  • 65.Ater JL, van Eys J, Woo SY, Moore B, Copeland DR, Bruner J. MOPP chemotherapy without irradiation as primary postsurgical therapy for brain tumors in infants and young children. J Neurooncol. 1997;32(3):243–252. doi: 10.1023/A:1005744527443. [DOI] [PubMed] [Google Scholar]
  • 66.White L, Johnston H, Jones R, Mameghan H, Nayanar V, Mc-Whirter W, Kellie S, Waters K, Toogood I. Postoperative chemotherapy without radiation in young children with malignant non-astrocytic brain tumours. A report from the Australia and New Zealand Childhood Cancer Study Group (ANZCCSG) Cancer Chemother Pharmacol. 1993;32(5):403–406. doi: 10.1007/BF00735928. [DOI] [PubMed] [Google Scholar]
  • 67.Kuhl JB, J, Bode U, Deinlein F., Gnekow A., Graf N., et al. Delayed radiation therapy (RT) after postoperative chemotherapy (PCH) in children less than 3 years of age with medulloblastoma. Results of the HIT-SKK’87 and preliminary results of the pilot trial HIT-SKK’92. Med Pediatr Oncol. 1995;25:250–250. [Google Scholar]
  • 68.Grill J, Sainte-Rose C, Jouvet A, Gentet JC, Lejars O, Frappaz D, Doz F, Rialland X, Pichon F, Bertozzi AI, Chastagner P, Couanet D, Habrand JL, Raquin MA, Le Deley MC, Kalifa C. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol. 2005;6(8):573–580. doi: 10.1016/S1470-2045(05)70252-7. [DOI] [PubMed] [Google Scholar]
  • 69.Dupuis-Girod S, Hartmann O, Benhamou E, Doz F, Mechinaud F, Bouffet E, Coze C, Kalifa C. Will high dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma? J Neurooncol. 1996;27(1):87–98. doi: 10.1007/BF00146088. [DOI] [PubMed] [Google Scholar]
  • 70.Guruangan S, Dunkel IJ, Goldman S, Garvin JH, Rosenblum M, Boyett JM, Gardner S, Merchant TE, Gollamudi S, Finlay JL. Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors. J Clin Oncol. 1998;16(7):2486–2493. doi: 10.1200/JCO.1998.16.7.2486. [DOI] [PubMed] [Google Scholar]
  • 71.Merchant TE, Happersett L, Finlay JL, Leibel SA. Preliminary results of conformai radiation therapy for medulloblastoma. Neuro-oncol. 1999;1(3):177–187. doi: 10.1093/neuonc/1.3.177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Wolden SL, Dunkel IJ, Souweidane MM, Happersett L, Khakoo Y, Schupak K, Lyden D, Leibel SA. Patterns of failure using a conformai radiation therapy tumor bed boost for medulloblastoma. J Clin Oncol. 2003;21(16):3079–3083. doi: 10.1200/JCO.2003.11.140. [DOI] [PubMed] [Google Scholar]
  • 73.Hallahan AR, Pritchard JI, Chandraratna RA, Ellenbogen RG, Geyer JR, Overland RP, Strand AD, Tapscott SJ, Olson JM. BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nat Med. 2003;9(8):1033–1038. doi: 10.1038/nm904. [DOI] [PubMed] [Google Scholar]
  • 74.Hirsch JF, Sainte Rose C, Pierre-Kahn A, Pfister A, Hoppe-Hirsch E. Benign astrocytic and oligodendrocytic tumors of the cerebral hemispheres in children. J Neurosurg. 1989;70(4):568–572. doi: 10.3171/jns.1989.70.4.0568. [DOI] [PubMed] [Google Scholar]
  • 75.Albright AL. Pediatric brain tumors. CA Cancer J Clin. 1993;43(5):272–288. doi: 10.3322/canjclin.43.5.272. [DOI] [PubMed] [Google Scholar]
  • 76.Kortmann RD, Timmermann B, Taylor RE, Scarzello G, Plasswilm L, Paulsen F, Jeremic B, Gnekow AK, Dieckmann K, Kay S, Bamberg M. Current and future strategies in radiotherapy of childhood low-grade glioma of the brain. Part I: Treatment modalities of radiation therapy. Strahlenther Onkol. 2003;179(8):509–520. doi: 10.1007/s00066-003-9104-9. [DOI] [PubMed] [Google Scholar]
  • 77.Rush JA, Younge BR, Campbell RJ, MacCarty CS. Optic glioma. Long-term follow-up of 85 histopathologically verified cases. Ophthalmology. 1982;89(11):1213–1219. [PubMed] [Google Scholar]
  • 78.Alvord EC, Lofton S. Gliomas of the optic nerve or chiasm. Outcome by patients’ age, tumor site, and treatment. J Neurosurg. 1988;68(1):85–98. doi: 10.3171/jns.1988.68.1.0085. [DOI] [PubMed] [Google Scholar]
  • 79.Deliganis AV, Geyer JR, Berger MS. Prognostic significance of type 1 neurofibromatosis (von Recklinghausen Disease) in childhood optic glioma. Neurosurgery. 1996;38(6):1114–1118. doi: 10.1097/00006123-199606000-00010. [DOI] [PubMed] [Google Scholar]
  • 80.Pierce SM, Barnes PD, Loeffler JS, McGinn C, Tarbeil NJ. Definitive radiation therapy in the management of symptomatic patients with optic glioma. Survival and long-term effects. Cancer. 1990;65(1):45–52. doi: 10.1002/1097-0142(19900101)65:1<45::AID-CNCR2820650111>3.0.CO;2-Z. [DOI] [PubMed] [Google Scholar]
  • 81.Radcliffe J, Packer RJ, Atkins TE, Bunin GR, Schut L, Goldwein JW, Sutton LN. Three- and four-year cognitive outcome in children with noncortical brain tumors treated with whole-brain radiotherapy. Ann Neurol. 1992;32(4):551–554. doi: 10.1002/ana.410320411. [DOI] [PubMed] [Google Scholar]
  • 82.Petronio J, Edwards MS, Prados M, Freyberger S, Rabbitt J, Silver P, Levin VA. Management of chiasmal and hypothalamic gliomas of infancy and childhood with chemotherapy. J Neurosurg. 1991;74(5):701–708. doi: 10.3171/jns.1991.74.5.0701. [DOI] [PubMed] [Google Scholar]
  • 83.Packer RJ, Lange B, Ater J, Nicholson HS, Allen J, Walker R, Prados M, Jakacki R, Reaman G, Needles MN, et al. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol. 1993;11(5):850–856. doi: 10.1200/JCO.1993.11.5.850. [DOI] [PubMed] [Google Scholar]
  • 84.Mahoney DH, Cohen ME, Friedman HS, Kepner JL, Gemer L, Langsten JW, James HE, Duffner PK, Kun LE. Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study. Neurooncol. 2000;2(4):213–220. doi: 10.1093/neuonc/2.4.213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Packer RJ, Ater J, Allen J, Phillips P, Geyer R, Nicholson HS, Jakacki R, Kurczynski E, Needle M, Finlay J, Reaman G, Boyett JM. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg. 1997;86(5):747–754. doi: 10.3171/jns.1997.86.5.0747. [DOI] [PubMed] [Google Scholar]
  • 86.Merchant TE, Zhu Y, Thompson SJ, Sontag MR, Heideman RL, Kun LE. Preliminary results from a Phase II trail of conformal radiation therapy for pediatric patients with localised low-grade astrocytoma and ependymoma. Int J Radiat Oncol Biol Phys. 2002;52(2):325–332. doi: 10.1016/S0360-3016(01)01807-7. [DOI] [PubMed] [Google Scholar]
  • 87.Saran FH, Baumert BG, Khoo VS, Adams EJ, Garre ML, Warrington AP, Brada M. Stereotactically guided conformal radiotherapy for progressive low-grade gliomas of childhood. Int J Radiat Oncol Biol Phys. 2002;53(1):43–51. doi: 10.1016/S0360-3016(02)02734-7. [DOI] [PubMed] [Google Scholar]
  • 88.Packer RJ, Boyett JM, Zimmerman RA, Rorke LB, Kaplan AM, Albright AL, Selch MT, Finlay JL, Hammond GD, Wara WM. Hyperfractionated radiation therapy (72 Gy) for children with brain stem gliomas. A Childrens Cancer Group Phase I/II Trial. Cancer. 1993;72(4):1414–1421. doi: 10.1002/1097-0142(19930815)72:4<1414::AID-CNCR2820720442>3.0.CO;2-C. [DOI] [PubMed] [Google Scholar]
  • 89.Broniscer A, Iacono L, Chintagumpala M, Fouladi M, Wallace D, Bowers DC, Stewart C, Krasin MJ, Gajjar A. Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98) Cancer. 2005;103(1):133–139. doi: 10.1002/cncr.20741. [DOI] [PubMed] [Google Scholar]
  • 90.Sanghavi SN, Needle MN, Krailo MD, Geyer JR, Ater J, Mehta MP. A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: first report of the Children’s Cancer Group-0952. Neuro-oncol. 2003;5(1):8–13. doi: 10.1093/neuonc/5.1.8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.Wisoff JH, Boyett JM, Berger MS, Brant C, Li H, Yates AJ, McGuire-Cullen P, Turski PA, Sutton LN, Allen JC, Packer RJ, Finlay JL. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children’s Cancer Group trial no. CCG-945. J Neurosurg. 1998;89(1):52–59. doi: 10.3171/jns.1998.89.1.0052. [DOI] [PubMed] [Google Scholar]
  • 92.Sposto R, Ertel IJ, Jenkin RD, Boesel CP, Venes JL, Ortega JA, Evans AE, Wara W, Hammond D. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group. J Neurooncol. 1989;7(2):165–177. doi: 10.1007/BF00165101. [DOI] [PubMed] [Google Scholar]
  • 93.Finlay JL, Boyett JM, Yates AJ, Wisoff JH, Milstein JM, Geyer JR, Bertolone SJ, McGuire P, Cherlow JM, Tefft M, et al. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group. J Clin Oncol. 1995;13(1):112–123. doi: 10.1200/JCO.1995.13.1.112. [DOI] [PubMed] [Google Scholar]
  • 94.Wolff JE, Gnekow AK, Kortmann RD, Pietsch T, Urban C, Graf N, Kuhl J. Preradiation chemotherapy for pediatric patients with high-grade glioma. Cancer. 2002;94(1):264–271. doi: 10.1002/cncr.10114. [DOI] [PubMed] [Google Scholar]
  • 95.Lashford LS, Thiesse P, Jouvet A, Jaspan T, Couanet D, Griffiths PD, Doz F, Ironside J, Robson K, Hobson R, Dugan M, Pearson AD, Vassal G, Frappaz D. Temozolomide in malignant gliomas of childhood: a United Kingdom Children’s Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol. 2002;20(24):4684–4691. doi: 10.1200/JCO.2002.08.141. [DOI] [PubMed] [Google Scholar]
  • 96.Dolan ME, Pegg AE. O6-benzylguanine and its role in chemotherapy. Clin Cancer Res. 1997;3(6):837–847. [PubMed] [Google Scholar]
  • 97.Warren K, Gervais A, Aikin A, Egorin M, Balis FM. Pharmaco-kinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors. Cancer Chemother Pharmacol. 2004;54(3):206–212. doi: 10.1007/s00280-004-0791-4. [DOI] [PubMed] [Google Scholar]
  • 98.Weber F, Asher A, Bucholz R, Berger M, Prados M, Chang S, Bruce J, Hall W, Rainov NG, Westphal M, Wamick RE, Rand RW, Floeth F, Rommel F, Pan H, Hingorani VN, Puri RK. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol. 2003;64(1–2):125–137. doi: 10.1007/BF02700027. [DOI] [PubMed] [Google Scholar]
  • 99.Di Sapio A, Mona I, Pradotto L, Guido M, Schiffer D, Mauro A. Molecular genetic changes in a series of neuroepithelial tumors of childhood. J Neurooncol. 2002;59(2):117–122. doi: 10.1023/A:1019697117253. [DOI] [PubMed] [Google Scholar]
  • 100.Raffel C, Frederick L, O’Fallon JR, Atherton-Skaff P, Perry A, Jenkins RB, James CD. Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. Clin Cancer Res. 1999;5(12):4085–4090. [PubMed] [Google Scholar]

Articles from NeuroRx are provided here courtesy of Am. Soc. for Experimental NeuroTherapeutics

RESOURCES